We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Accepts Sandoz’s Application for Biosimilar of Amgen’s Enbrel
FDA Accepts Sandoz’s Application for Biosimilar of Amgen’s Enbrel
Sandoz says the FDA has accepted its second biosimilar application, this one for a copy of Amgen’s autoimmune disease drug Enbrel, whose global sales of nearly $9 billion made it the world’s fifth-biggest selling medicine in 2014.